NASDAQ: LABT#6 smallestClinical-stage antimicrobialsUnited States
Lakewood-Amedex Biotherapeutics Inc.
$0.19505.41%USD · Nasdaq, delayed
Key statistics
Market cap$462.1K
Volume880,851
52-week high$98.20
52-week low$0.1687
From 52-week high-99.80%
Shares (implied)2,369,687
1% stake costs$4.6K
Listing config4bWZb…fiSce ↗
About Lakewood-Amedex
Florida clinical-stage biotech developing Bisphosphocins, a new class of fast-acting, broad-spectrum antimicrobials aimed at resistant strains such as MRSA and VRE. Lead candidate Nu-3 has completed Phase 1 and an exploratory Phase 2, and is heading into a Phase 2a in infected diabetic foot ulcers.
Why it’s listed
About $4.3M of book equity at June 30, almost all current assets, against a market cap under $0.5M. The market is putting a negative value on a clinical-stage antibiotic pipeline.
Main risk
Binary clinical readouts, and every trial will need new money. Series C preferred is still convertible into common, and the company reverse-split 1-for-10 in June.
The bid
LIVERaised
…
SOL
Stake funded
0%
- 1% stake$4.6KTop-holder list on most micro-caps
- 5% stake$23.1KSchedule 13D/13G beneficial-owner filing
- 10% stake$46.2KSection 16 insider status
- 50.1% stake$231.5KMajority control of the vote
Costs at the last price, before market impact.